Hearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides
- 20 June 2013
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 60 (11) , 1772-1777
Abstract
Background Children undergoing cancer therapy often receive aminoglycosides to treat febrile neutropenia or gram-negative infections. The magnitude of the risk of developing aminoglycoside-induced ototoxicity and the dose threshold at which that risk significantly increases are unknown. Procedure Eligible cancer patients received the aminoglycoside amikacin at Children's Medical Center between 2004 and 2007. They were aged 3–8 years; were without prior hearing loss; had no platinum-based chemotherapy, cranial radiation, nor bone marrow transplant; and received no loop diuretics within 6 weeks of testing. Consenting patients underwent complete hearing and vestibular testing. Results We tested 23 patients who had significant amikacin exposure. Three (13%) had abnormal hearing tests, and four (17%) had subclinical vestibular dysfunction; none had both. Of those with hearing loss, two were known to have developed hearing loss after aminoglycoside exposure, but the third had moderate to severe high-frequency sensorinueral hearing loss bilaterally that had been undiagnosed. We observed clear dose-dependent ototoxicity; of the eight patients who received amikacin for a cumulative total of more than 50 days, five (68%) developed toxicity. Similarly, of the seven who received a cumulative total of more than 1,200 mg/kg, five developed toxicity. Conclusions These data highlight the risks of prolonged aminoglycoside administration and warrant further validation in a larger group of patients. Patients to be treated with prolonged aminoglycoside therapy may benefit from prospective hearing screening. Pediatr Blood Cancer 2013;60:1772–1777.Keywords
This publication has 30 references indexed in Scilit:
- Cellular mechanisms of aminoglycoside ototoxicityCurrent Opinion in Otolaryngology & Head and Neck Surgery, 2010
- Protective effect of edaravone against tobramycin-induced ototoxicityActa Oto-Laryngologica, 2009
- Twenty-five–year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor StudyBlood, 2008
- Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteineKidney International, 2007
- Chronic Health Conditions in Adult Survivors of Childhood CancerNew England Journal of Medicine, 2006
- Aspirin to Prevent Gentamicin-Induced Hearing LossNew England Journal of Medicine, 2006
- Extremely low penetrance of deafness associated with the mitochondrial 12S rRNA mutation in 16 Chinese families: Implication for early detection and prevention of deafnessBiochemical and Biophysical Research Communications, 2006
- Vestibular Rehabilitation Therapy in ChildrenOtology & Neurotology, 2005
- Audiologic Testing and Molecular Analysis of 12S rRNA in Patients Receiving AminoglycosidesThe Laryngoscope, 2005
- Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancerThe Pediatric Infectious Disease Journal, 1997